Structure-based design of potent non-peptide MDM2 inhibitors.

By Ke Ding, Yipin Lu, Zaneta Nikolovska-Coleska, S. Qiu, Yousong Ding, Wei-Lin Gao, J. Stuckey, K. Krajewski, P. Roller, Y. Tomita and 3 more. Journal of the American Chemical Society, 2005

616 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Organic Chemistry

View Paper: https://www.semanticscholar.org/paper/0844b0e2823875331c639bf4a36e5b4189b03498

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Carol Prives
2. Karen H. Vousden
3. Vladimir N Uversky
4. W. Gu

In Oncology

1. Carol Prives
2. Karen H. Vousden
3. Vladimir N Uversky
4. W. Gu

Citations in the corpus

• Blinded by the Light: The Growing Complexity of p53. (2009, background): “, 2004) and compound 1d (Ding et al., 2005), which bind to Mdm2 and disrupt the interaction between Mdm2 and TAD I of p53, can greatly increase p53 expression and activity (Ding et al.”